当前位置:
首页
网刊
有机阴离子转运多肽4C1介导的肾脏转运及其临床价值
有机阴离子转运多肽4C1介导的肾脏转运及其临床价值
何佳珂1,于 洋1,桂 环2,王永龙1,李义秀1,熊爱珍1

1 南昌大学第二附属医院药学部,南昌 330006;2 苏州大学附属儿童医院药学部,苏州 215000
Organic anion-transporting polypeptide 4C1 mediated renal transport and its clinical significance
(1 Department of Pharmacy, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China; 2 Department of Pharmacy, Children's Hospital of Soochow University, Suzhou 215000, China)

摘要参考文献相关文章

起始页:1516

摘要:[摘要] OATP4C1是唯一表达在肾脏的OATP家族转运体,参与多种内、外源性化合物(如甲状腺激素、强心苷类药物、尿毒症毒素等)的跨膜转运,在机体清除过程中发挥着不可替代的作用。本文从OATP4C1的分子生物学基础、主要功能、介导的肾脏转运及其临床价值进行综述,以期从分子水平阐明并预警临床治疗中由转运体介导的药物相互作用及其引发的不良反应,找寻基于药物转运体的疾病治疗新策略,促进临床用药的安全有效。

关键词:[关键词] 有机阴离子转运多肽4C1(OATP4C1);肾脏转运;临床价值

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] As the only transporter expressed in kidney in OATP family, OATP4C1 participates in the transmembrane transport of various endogenous substances and xenobiotics, including thyroid hormone, cardiac glucosides and uremic toxins, which plays a vital role in the elimination process. This paper summarizes the structure and major function of OATP4C1, as well as its renal transport and associated clinical significance under the goal of exploring transporter-guided therapeutic strategy and preventing transporter mediated clinical drug-drug interaction.

Key words:[Key words] organic anion-transporting polypeptide 4C1(OATP4C1);renal transport;clinical significance

    [1] LAUNAY-VACHER V, IZZEDINE H, KARIE S, et al. Renal tubular drug transporters[J]. Nephron Physiol, 2006, 103(3): 97-106.
    [2] YIN J, WANG J. Renal drug transporters and their significance in drug-drug interactions[J]. Acta Pharm Sin B, 2016, 6(5): 363-373.
    [3] PRASAD B, JOHNSON K, BILLINGTON S, et al. Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics[J]. Drug Metab Dispos, 2016, 44(12): 1920-1924.
    [4] MOTOHASHI H, NAKAO Y, MASUDA S, et al. Precise comparison of protein localization among OCT, OAT, and MATE in human kidney[J]. J Pharm Sci, 2013, 102(9): 3302-3308.
    [5] NIGAM SK, WU W, BUSH KT, et al. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters[J]. Clin J Am Soc Nephrol, 2015, 10(11): 2039-2049.
    [6] TIAN Y, BIAN Y, JIANG Y, et al. Interplay of breast cancer resistance protein (BCRP) and metabolizing enzymes[J]. Curr Drug Metab, 2015, 16(10): 877-893.
    [7] NIESKENS TT, PETERS JG, SCHREURS MJ, et al. A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity[J]. AAPS J, 2016, 18(2): 465-475.
    [8] KOREN G. Clinical pharmacokinetic significance of the renal tubular secretion of digoxin[J]. Clin Pharmacokinet, 1987, 13(5): 334-343.
    [9] HAGENBUCH B, MEIER PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties[J]. Pflugers Arch, 2004, 447(5): 653-665.
    [10] KALLIOKOSKI A, NIEMI M. Impact of OATP transporters on pharmacokinetics[J]. Br J Pharmacol, 2009, 158(3): 693-705.
    [11] MIKKAICHI T, SUZUKI T, ONOGAWA T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney[J]. Proc Natl Acad Sci USA, 2004, 101(10): 3569-3574.
    [12] SCHWENK MH, PAI AB. Drug transporter function——implications in CKD[J]. Adv Chronic Kidney Dis, 2016, 23(2): 76-81.
    [13] YAMAGUCHI H, SUGIE M, OKADA M, et al. Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1[J]. Drug Metab Pharmacokinet, 2010, 25(3):314-317.
    [14] HE J, YU Y, PRASAD B, et al. Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction[J]. Biopharm Drug Dispos, 2014, 35(5): 253-263.
    [15] CHU XY, BLEASBY K, YABUT J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein[J]. J Pharmacol Exp Ther, 2007, 321(2): 673-683. 
    [16] KUO KL, ZHU H, MCNAMARA PJ, et al. Localization and functional characterization of the rat Oatp4c1 transporter in an in vitro cell system and rat tissues[J]. PLoS One, 2012, 7(6): e39641. 
    [17] KIRBY BJ, COLLIER AC, KHARASCH ED, et al. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion[J]. Drug Metab Dispos, 2012, 40(3): 610-616.
    [18] ABE T, SUZUKI T, UNNO M, et al. Thyroid hormone transporters: recent advances[J]. Trends Endocrinol Metab, 2002, 13(5): 215-220.
    [19] FRIESEMA EC, DOCTER R, MOERINGS EP, et al. Identification of thyroid hormone transporters[J]. Biochem Biophys Res Commun, 1999, 254(2): 497-501.
    [20] FRIESEMA EC, DOCTER R, MOERINGS EP, et al. Thyroid hormone transport by the heterodimeric human system L amino acid transporter[J]. Endocrinology, 2001, 142(10): 4339-4348.
    [21] LEE WS, BERRY MJ, HEDIGER MA, et al. The type I iodothyronine 5'-deiodinase messenger ribonucleic acid is localized to the S3 segment of the rat kidney proximal tubule[J]. Endocrinology, 1993, 132(5): 2136-2140.
    [22] MASEREEUW R, MUTSAERS HA, TOYOHARA T, et al. The kidney and uremic toxin removal: glomerulus or tubule?[J]. Semin Nephrol, 2014, 34(2):191-208.
    [23] TOYOHARA T, SUZUKI T, MORIMOTO R, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation[J]. J Am Soc Nephrol, 2009, 20(12): 2546-2555.
    [24] AKIYAMA Y, KIKUCHI K, SAIGUSA D, et al. Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3[J]. PLoS One, 2013, 8(7): e66518.
    [25] SUZUKI T, TOYOHARA T, AKIYAMA Y, et al. Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease[J]. J Pharm Sci, 2011, 100(9): 3696-3707.